Adcetris® is the commercial brand name of Brentuximab Vedotin for Injection, an antibody-drug conjugate developed by Seagen. It binds to CD30 antigen on malignant lymphoma cells and releases cytotoxic agent inside tumor cells to induce cell apoptosis. Main IndicationsTreatment of…
Takhzyro® is the commercial brand name of Lanadelumab Injection, a fully human monoclonal antibody developed by Shire. It selectively binds to plasma kallikrein to inhibit its enzymatic activity, lowering bradykinin overproduction and preventing hereditary angioedema attacks. Main IndicationsRoutine prophylaxis to…
Enhertu® is the commercial brand name of Trastuzumab Deruxtecan for Injection, an antibody-drug conjugate jointly developed by Daiichi-Sankyo and AstraZeneca. It targets HER2 antigen on tumor cell surface to deliver cytotoxic payload into cancer cells and induce tumor cell death.…
Aricept® is the commercial brand name of Donepezil Hydrochloride Tablets, an orally active reversible acetylcholinesterase inhibitor developed by Eisai. It elevates cerebral acetylcholine level to improve cognitive function in dementia patients. Main IndicationsSymptomatic treatment for mild to moderate Alzheimer’s disease.…
Leqembi® is the commercial brand name of Lecanemab Injection, a humanized monoclonal antibody jointly developed by Eisai and Biogen. It targets soluble aggregated amyloid-beta in the brain to clear cerebral amyloid deposits and slow disease progression of Alzheimer’s disease. Main…
Azilect® is the commercial brand name of Rasagiline Mesylate Tablets, an orally active irreversible monoamine oxidase-B inhibitor developed by Teva. It elevates intracerebral dopamine concentration to improve motor symptoms of Parkinson’s disease. Main IndicationsMonotherapy for early Parkinson’s disease;Adjunctive treatment combined…
Quviviq® is the commercial brand name of Daridorexant Hydrochloride Tablets, an orally active dual orexin receptor antagonist manufactured by Simcere Pharmaceutical. It blocks orexin receptors in the central nervous system to inhibit wake-promoting signaling and improve sleep onset and maintenance.…
Lorbrena® is the commercial brand name of Lorlatinib Tablets, an orally active third-generation selective ALK/ROS1 tyrosine kinase inhibitor developed by Pfizer. It potently inhibits mutated ALK kinase to block downstream oncogenic signaling and suppress tumor proliferation, including multiple crizotinib-resistant ALK…
Alunbrig® is the commercial brand name of Brigatinib Tablets, an orally active dual ALK/EGFR tyrosine kinase inhibitor developed by Takeda Pharmaceutical. It blocks abnormal ALK-driven downstream signaling cascade to suppress proliferation of ALK-rearranged tumor cells. Main IndicationsTreatment for adult patients…
Zelboraf® is the commercial brand name of Vemurafenib Tablets, an orally active BRAF serine/threonine kinase inhibitor developed by Roche. It selectively inhibits mutant BRAF V600 kinase to block abnormal MAPK signaling pathway and restrain proliferation of BRAF V600-mutated tumor cells.…